Atea Pharmaceuticals (AVIR) Asset Utilization Ratio (2021)

Atea Pharmaceuticals (AVIR) recorded quarterly Asset Utilization Ratio of 0.43 in Q4 2021.

Atea Pharmaceuticals (AVIR) Asset Utilization Ratio (2021) Analysis & Trends

Atea Pharmaceuticals' Asset Utilization Ratio history runs 1 years deep, the most recent figure standing at 0.43 for Q4 2021.

In Q4 2021, Asset Utilization Ratio changed N/A year-over-year to 0.43; the TTM figure through Dec 2021 stood at 0.43 (changed N/A YoY), while the FY2021 annual figure was 0.43, up 291.02% from the prior year.
Asset Utilization Ratio was 0.43 for Q4 2021 at Atea Pharmaceuticals.
In the past five years, Asset Utilization Ratio ranged from a high of 0.43 in Q4 2021 to a low of 0.43 in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	0.55
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	0.60
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	1,422.00
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	0.47
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Atea Pharmaceuticals	347.28 Mn	347.28 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	0.43